465 related articles for article (PubMed ID: 21326118)
1. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
2. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
Torino F; Barnabei A; De Vecchis L; Appetecchia M; Strigari L; Corsello SM
Endocr Relat Cancer; 2012 Apr; 19(2):R21-33. PubMed ID: 22241718
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer.
Torino F; Barnabei A; De Vecchis L; Sini V; Schittulli F; Marchetti P; Corsello SM
Crit Rev Oncol Hematol; 2014 Jan; 89(1):27-42. PubMed ID: 23953684
[TBL] [Abstract][Full Text] [Related]
4. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
[TBL] [Abstract][Full Text] [Related]
5. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
Guerrero A; Gavilá J; Folkerd E; Ortiz B; Martínez F; García A; Climent MA; Guillem V; Ruíz A
Ann Oncol; 2013 Mar; 24(3):674-9. PubMed ID: 23108951
[TBL] [Abstract][Full Text] [Related]
8. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Ortmann O; Pagani O; Jones A; Maass N; Noss D; Rugo H; van de Velde C; Aapro M; Coleman R
Cancer Treat Rev; 2011 Apr; 37(2):97-104. PubMed ID: 20594763
[TBL] [Abstract][Full Text] [Related]
9. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
10. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival.
Collichio F; Pandya K
Oncology (Williston Park); 1994 Dec; 8(12):45-52. PubMed ID: 7888312
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.
Panidis D; Katsikis I; Karkanaki A; Piouka A; Armeni AK; Georgopoulos NA
Med Hypotheses; 2011 Oct; 77(4):649-53. PubMed ID: 21807466
[TBL] [Abstract][Full Text] [Related]
12. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer.
Han W; Kim H; Ku SY; Kim SH; Choi YM; Kim JG; Moon SY
Gynecol Endocrinol; 2013 Jan; 29(1):16-9. PubMed ID: 22812679
[TBL] [Abstract][Full Text] [Related]
14. Ovarian function and childbearing issues in breast cancer survivors.
Gadducci A; Cosio S; Genazzani AR
Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
[TBL] [Abstract][Full Text] [Related]
15. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
16. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
[TBL] [Abstract][Full Text] [Related]
17. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
18. Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Henry NL; Xia R; Banerjee M; Gersch C; McConnell D; Giacherio D; Schott AF; Pearlman M; Stearns V; Partridge AH; Hayes DF
Ann Oncol; 2013 Aug; 24(8):2011-6. PubMed ID: 23613476
[TBL] [Abstract][Full Text] [Related]
19. [Hormone therapy in breast cancer: the end of tamoxifen?].
Delozier T
Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
[TBL] [Abstract][Full Text] [Related]
20. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause.
La Marca A; De Leo V; Giulini S; Orvieto R; Malmusi S; Giannella L; Volpe A
J Soc Gynecol Investig; 2005 Oct; 12(7):545-8. PubMed ID: 16046154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
